Amylyx 2024 Q4 Earnings Record Net Loss of 893.6%

Amylyx (AMLX) reported its fiscal 2024 Q4 earnings on August 8, 2025, revealing a dramatic shift in performance. The company significantly missed expectations, with a net loss of $-37.55 million, or $0.55 per share, compared to a profit of $0.07 per share in the prior-year quarter. The company did not raise or adjust its guidance, and results were in line with expectations of continued financial pressure.

Revenue
Total revenue for the quarter plunged by 100.6% to $-665,000, a steep decline from $108.45 million in the same period of 2023. The negative revenue reflects the company's continued focus on research and development rather than commercial revenue generation at this stage.

Earnings/Net Income
Amylyx swung to a loss of $0.55 per share in Q4 2024, compared to a profit of $0.07 per share in the prior-year period, representing an 882.7% negative change. The net loss widened to $-37.55 million, down from a net income of $4.73 million in Q4 2023, a deterioration of 893.6%. This marks a record low in the company’s earnings performance.

Price Action
The stock price of Amylyx fell 2.00% during the latest trading day and declined further by 2.37% over the most recent full trading week. However, it posted a 12.32% gain month-to-date, indicating some short-term investor optimism despite the earnings miss.

Post Earnings Price Action Review
A strategy of buying Amylyx shares following a revenue decline quarter-over-quarter and holding for 30 days has historically yielded no return over the past three years. This approach produced a compound annual growth rate (CAGR) of 0.00% and an excess return of -47.91%, significantly underperforming the benchmark. The strategy exhibited zero volatility and maximum drawdown, suggesting a risk-averse approach that failed to generate value.

CEO Commentary
Josh Cohen, Co-CEO of Amylyx, emphasized the company’s continued focus on its pipeline of investigational therapies targeting high unmet medical needs. Key developments include the first participant dosed in the Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia (PBH) and positive Week 48 data from the Phase 2 HELIOS trial of AMX0035 for Wolfram syndrome and progressive supranuclear palsy (PSP). The company is also advancing AMX0114 for amyotrophic lateral sclerosis (ALS).

Guidance
Amylyx expects to complete enrollment for the Phase 3 LUCIDITY trial of avexitide in PBH by 2025, with data anticipated in early 2026. The company also expects safety and efficacy data from the Phase 2b portion of the ORION trial for AMX0035 in PSP by Q3 2025 and early cohort data from the Phase 1 LUMINA trial of AMX0114 in ALS in 2025.

Additional News
Recent global news highlights include escalating tensions over the Gaza plan ahead of a cabinet meeting, concerns over the humanitarian crisis in Gaza, and political developments in Taiwan. In economic policy, the U.S. is grappling with new tariff measures and a potential meeting between Trump and Putin. Meanwhile, international trade and diplomatic relations remain under scrutiny, with particular focus on China-U.S. ties and the impact of tariffs on global markets.